Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells

References

• AMREIN, R. and HETZEL, W., 1990, Pharmacology of Dormicumcg)(midazolam) and Anexate (fiumazenil). Ada Anaesthesiologica Scandinavica, 34, 6–15.
   Google Scholar
• ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIREETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
   PubMed Web of Science ®Google Scholar
• ASHFORTH, E. I. L., CARLILE, D. J., CHENERY, R. and HOUSTON, J. B., 1995, Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. Journal of Pharmacology and Experimental Therapeutics, 274, 761–766.
   Google Scholar
• BLAKE, J. A. R., PRITCHARD, M., DING, S., SMITH, G. C. M., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1996, Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. Federation of European Biochemical Societies Letters, 397, 210–214.
   Google Scholar
• CHEN, Z. R., SOMOGYI, A. A. and BOCHNER, F., 1990, Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high performance liquid chromatography with application to their disposition in man. Therapeutic Drug Monitoring, 12, 97–104.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L., 1995, Xenobiotic-metabolising human cells as tools for pharmacological and toxicological research. Advances in Drug Research, 26, 179–235.
   Google Scholar
• CRESPI, C. L. and PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug—drug interactions. Advances in Pharmacology, 43, 171–188.
   PubMedGoogle Scholar
• DUCHARME, J., ABDULLAH, S. and WAINER, I. W., 1996, Dextromethorphan as an in vitro probe for the simultaneous determination of CYP2D6 and CYP3A4 activity. Journal of Chromatography B, 678, 113–128.
   PubMedGoogle Scholar
• FRIEDBERG, T. and WOLF, C. R., 1996, Recombinant DNA technology as an investigative tool in drug metabolism research. Advanced Drug Delivery Reviews, 22, 187–213.
   Web of Science ®Google Scholar
• GHOSAL, A., SATOH, H., THOMAS, P. E., Bust', E. and MOORE, D., 1996, Inhibition and kinetic of cytochrome P4503A activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   Google Scholar
• GILLAM, E. M. J., BABA, T., Kim, B.-R., OHMORI, S. and GUENGERICH, F. P., 1993, Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Archives of Biochemistry and Biophysics, 305, 123–131.
   Google Scholar
• GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Cytochrome P450 expression systems. Annual Review of Pharmacology and Toxicology, 35, 369–390.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994b, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1994a, Characterisation of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450 3A subfamily. Biochemical Pharmacology, 48, 173–182.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., BRIAN, W. R., SARI, M. A. and Ross, J. T., 1991, Expression of mammalian cytochrome P450 enzymes using yeast-based vectors. In M. R. Waterman and E. F. Johnson (eds), Methods in Enzymology (New York: Academic Press), pp. 130–148.
   Google Scholar
• HICKMAN, D., WANG, J., WANG, Y. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• IWATA, H., FUJITA, K.-I., KUSHIDA, H., SUZUKI, A., KONNO, Y., NAKAMURA, K., FUJIN°, A. and KAMATAKI, T., 1998, High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochemical Pharmacology, 55, 1315–1325.
   Google Scholar
• JACQZ-AIGRAIN, E., FUNCK-BRENTANO, C. and CRESTEIL, T., 1993, CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3, 197–204.
   PubMedGoogle Scholar
• JUNG, F., RICHARDSON, T. H., RAUCY, J. L. and JOHNSON, E. F., 1997, Diazepam metabolism by cDNA-expressed human 2C P450s identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metabolism and Disposition, 25, 133–139.
   PubMed Web of Science ®Google Scholar
• KERRY, N. L., SOMOGYI, A. A., BOCHNER, F. and Mutus, G., 1994, The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology, 38, 243–248.
   PubMed Web of Science ®Google Scholar
• KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Molecular Pharmacology, 36, 89–96.
   PubMed Web of Science ®Google Scholar
• LEE, C. A., KADWELL, S. H., KOST, T. A. and SERBJIT-SINGH, C. J., 1995, CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Archives of Biochemistry and Biophysics, 319, 157–167.
   Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RkNDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MAENPAA, J., HALL, S. D., RING, B. J., STROM, S. C. and WElmuroN, S. A., 1998, Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by a-naphthofiavone, terfenadine and testosterone. Pharmacogenetics, 8, 137–155.
   PubMedGoogle Scholar
• MCGINNITY, D. F., GRIFFIN, S. J., MOODY, G. C., VOICE, M., HANLON, S., FRIEDBERG, T. and RILEY, R. J., 1999, Rapid characterisation of the major drug-metabolising human hepatic cytochrome P-450 enzyme expressed in Escherichia coli. Drug Metabolism and Disposition, 27, 1017–1023.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• PEYRONNEAU, M.-A., RENAUD, J.-P., TRUAN, G., URBAN, P., POMPON, D. and MANSUY, D., 1992, Optimisation of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome bs. European Journal of Biochemistry, 207, 109–116.
   PubMedGoogle Scholar
• REILLY, P. E. B., THOMPSON, D. A., MASON, S. R. and HOOPER, W. D., 1990, Cytochrome P450IIIA enzymes in rat microsomes: involvement in C3-hydroxylation of diazepam and nordazeparn but not N-dealkylation of diazepam and temazepam. Molecular Pharmacology, 37, 767–774.
   Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SHOU, M., MEI, Q., ETTORE, M. W., Dm, R., BAILLIE, T. A. and RUSHMORE, T. H., 1999, Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochemical Journal, 340, 845–853.
   PubMed Web of Science ®Google Scholar
• VERMILION, J. L. and COON, M. J., 1978, Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterisation of oxidation—reduction states. Journal of Biological Chemistry, 253, 2694–2704.
   PubMed Web of Science ®Google Scholar
• VOICE, M. W., ZHANG, Y., WOLF, C. R., BURCHELL, B. and FRIEDBERG, T., 1999, Effects of human cytochrome bs on CYP3A4 activity and stability in vivo. Archives of Biochemistry and Biophysics, 366, 116–124.
   PubMed Web of Science ®Google Scholar
• WITHEROW, L. E. and HOUSTON, J. B., 1999, Sigmoidal kinetics of CYP3A substrates: An approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. Journal of Pharmacology and Experimental Therapeutics, 290, 58–65.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., NAKAJIMA, M., NAKAMURA, M., ASAHI, S., SHIMADA, N., GILLAM, E. M. J., GUENGERICH, F. P., SHIMADA, T. and YoNol, T., 1999, Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome bs in bacterial membranes. Drug Metabolism and Disposition, 27, 999–1004.
   Google Scholar
• YANG, T. J., SHou, M., KORZEKWA, K. R., GONZALEZ, F. J., GELBOIN, H. V. and YANG, S. K., 1998, Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochemical Pharmacology, 55, 889–896.
   PubMed Web of Science ®Google Scholar
• YU, A. and HAINING, L. R., 2001, Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Drug Metabolism and Disposition, 29, 1514–1520.
   Google Scholar
• ZOMORODI, K. and HOUSTON, J. B., 1996, Diazepam—omeprazole inhibition interactions: an in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology, 42, 157–162.
   PubMed Web of Science ®Google Scholar